Every drug approved for endometriosis works by turning down a hormone. A small company called EndoCyclic Therapeutics now has clearance to test one that does not.
The FDA cleared the company's investigational new drug application for ENDO-205 on March 23, EndoCyclic said in announcing the milestone ↗. ENDO-205 is a peptide, and the company calls it the first non-hormonal therapy designed to remove endometriosis lesions rather than quiet the symptoms they cause. The IND clearance is the regulatory green light to begin testing it in people. A Phase 1 study in healthy pre-menopausal women is planned next.
To see why a non-hormonal option is a real departure, look at what endometriosis treatment is now. The disease happens when tissue like the lining of the uterus grows outside it, on the ovaries, the bowel, the pelvic wall, where it bleeds and inflames on the same monthly cycle as the uterus and causes pain that can be disabling. It affects roughly one in ten women of reproductive age, around 190 million people worldwide. The drugs aimed at it all pull the same lever: cut estrogen, because estrogen is what feeds the misplaced tissue. Leuprolide ↗, sold as Lupron, is a peptide that shuts down the pituitary signal driving the ovaries. Newer pills like elagolix (Orilissa) and relugolix (sold in Myfembree) block the same GnRH receptor ↗ more directly. They can shrink lesions and dull pain, but they do it by pushing the body toward a chemical menopause, with the bone loss, hot flashes, and mood effects that come with it, and the disease tends to return once the drug stops.
ENDO-205 is pitched as a different kind of thing. EndoCyclic says it targets diseased tissue directly and is built to avoid hormonal manipulation, surgery, immune suppression, and broad toxicity. In animal models, the company reports, the peptide eliminated lesions and the inflammation around them, with no safety signals in the formal toxicology studies that support a first human trial. Founder and chief executive Tanya Petrossian said the clearance "validates the strong scientific foundation behind ENDO-205." The program has been funded by repeat awards from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and was named an NIH Small Business Innovation Research success story.
Here is the part worth keeping skeptical about. The company has not disclosed what ENDO-205 actually binds or the sequence of the peptide, describing it only as a product of its precision peptide platform. The lesion-clearing results are in animals, and the human program is at its earliest possible point, a Phase 1 whose first job is to show the drug is safe in healthy volunteers, not that it does anything to endometriosis. First-in-class mechanisms in this disease have a long history of looking clean in mice and stalling in the clinic. Nothing here is proven in a patient yet.
What makes it worth flagging anyway is the shape of the gap it aims at. Endometriosis research has been starved of money and ideas for decades, and almost every tool a patient is offered, from Lupron to the newest pill, is a variation on lowering estrogen. A peptide that goes after the lesion itself, if it survives contact with human trials, would be the first mechanistic alternative rather than another hormone switch. That is a large if. The IND clearance does not shrink it. It just means the question finally gets asked in people.
On our platform, the existing hormonal route already has a face. Leuprolide sits as a GnRH agonist card ↗, a peptide that works by exhausting the receptor it hits, the opposite design philosophy from a drug that tries to leave hormones alone and act on the tissue. ENDO-205 has no card yet, because there is no public sequence to build one from. If EndoCyclic ever discloses the target, it will be one of the more interesting entries the endometriosis shelf has had in years.